SAN FRANCISCO, March 24 /PRNewswire/ -- Epiphany Biosciences announced today that the company plans on filing an IND with the Food and Drug Administration (FDA) to study the potential impact of using the antiviral medication valomaciclovir (EPB-348) as an adjunctive therapy in the treatment of multiple sclerosis.
Valomaciclovir has been shown to possess potent antiviral activity in vitro against a number of herpes-related viruses, including herpes simplex (HSV), Epstein-Barr virus (EBV), herpes zoster (HZV), and human herpes virus 6 (HHV-6). The drug is currently being tested in a phase 2b study in patients with acute herpes zoster infection (shingles) and in a phase 2a study in patients with acute infectious mononucleosis.
"There has been accumulating evidence that MS may be the result of multiple contributing factors, including infection by the Epstein-Barr virus," stated Fred Volinsky, MD, CEO of Epiphany. "Based on these data, we feel this is the right time to explore the potential use of valomaciclovir to help manage this illness that can affect young adults as well as children."
Multiple sclerosis is a chronic, and often progressive demyelinating illness of the central nervous system, occurring with a noted predominance among women. "MS affects approximately 2.5 million people worldwide and appears to result from an interplay between genetic and environmental factors which taken together, increase a person's likelihood of developing the disease. MS is also increasing in frequency worldwide. Some progress in managing the symptoms of MS has been achieved with the use of immunomodulatory therapies. This program would be the first foray into potentially augmenting immunomodulatory therapeutics with a medicine specifically targeted at a suspected infectious cause, the Epstein-Barr virus," commented Stephen Hauser, MD, Chair of the Department of Neurology at the
SOURCE Epiphany Biosciences
Copyright©2009 PR Newswire.
All rights reserved
Related medicine news :
1. Pressure BioSciences, Inc. Provides Corporate Update
2. BIND Biosciences To Install First Siemens Simatic(R) PCS 7 Lab Process Control System in the U.S.
3. Cell Biosciences Announces First UK System Sale
4. Regado Biosciences to Present at the 2009 Wharton Healthcare Business Conference
5. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2008 Results
6. Enlight Biosciences Expands to direct up to $52 Million to Transformational Enabling Technologies
7. New Jersey-Based Biotech Start-Up Nexomics Biosciences Gets Off the Ground
8. URMC, Lighthouse Biosciences Awarded U.S. Patent for Diagnostic Technology
9. URMC, Lighthouse Biosciences awarded US patent for diagnostic technology
10. Abbott Completes Acquisition of Ibis Biosciences, a Subsidiary of Isis
11. CeloNova BioSciences Receives FDA Market Approval for Embozene(TM) Color-Advanced Microspheres Embolization Platform